Credit Suisse AG cut its stake in NewLink Genetics Corporation (NASDAQ:NLNK) by 15.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,868 shares of the biotechnology company’s stock after selling 4,887 shares during the period. Credit Suisse AG owned approximately 0.09% of NewLink Genetics Corporation worth $648,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Endurant Capital Management LP purchased a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $1,433,000. Gotham Asset Management LLC purchased a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $313,000. Bank of America Corp DE raised its position in shares of NewLink Genetics Corporation by 361.8% in the first quarter. Bank of America Corp DE now owns 31,911 shares of the biotechnology company’s stock valued at $769,000 after buying an additional 25,001 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of NewLink Genetics Corporation by 21.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,369 shares of the biotechnology company’s stock valued at $2,082,000 after buying an additional 14,975 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of NewLink Genetics Corporation by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 86,143 shares of the biotechnology company’s stock valued at $2,076,000 after buying an additional 22,165 shares during the last quarter. Institutional investors and hedge funds own 54.78% of the company’s stock.

Shares of NewLink Genetics Corporation (NASDAQ NLNK) traded down 1.32% during mid-day trading on Tuesday, hitting $6.72. The stock had a trading volume of 71,853 shares. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The stock’s 50-day moving average price is $7.06 and its 200-day moving average price is $13.17. The firm’s market cap is $197.71 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. On average, analysts anticipate that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/credit-suisse-ag-sells-4887-shares-of-newlink-genetics-corporation-nlnk/1529918.html.

Several research analysts have issued reports on the company. Jefferies Group LLC set a $7.00 price target on NewLink Genetics Corporation and gave the stock a “hold” rating in a report on Friday. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics Corporation and gave the stock a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 9th. Finally, Robert W. Baird downgraded NewLink Genetics Corporation from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $25.00 to $8.00 in a research note on Thursday, June 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $18.17.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corporation (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.